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Collagen cross-linking (CXL) using UVA light and riboﬂavin (vitamin B2) was introduced as a clinical application to stabilize the
cornea by inducing cross-links within and between collagen ﬁbers. CXL has been investigated extensively and has been shown
clinically to arrest the progression of keratoconic or post-LASIK ectasia. With its minimal cost, simplicity, and proven positive
clinical outcome, CXL can be regarded as a useful approach to reduce the number of penetrating keratoplasties performed. Small
case series have also indicated that CXL is beneﬁcial in corneal edema by reducing stromal swelling behavior and in keratitis by
inhibiting pathogen growth. Despite these encouraging results, CXL remains a relatively new method that is potentially associated
with complications. Aspects such as side eﬀects and recurrence rates have still to be elucidated. In light of the growing interest in
CXL, our paper summarizes present knowledge about this promising approach. We have intentionally endeavored to include the
more relevant studies from the recent literature to provide an overview of the current status of CXL.
1.Introduction
Keratoconusisanoninﬂammatory,usuallybilateraldisorder,
which manifests as progressive corneal instability character-
ized by abnormal thinning and steepening of the cornea [1].
This abnormal curvature of the cornea changes its refractive
power, often resulting in irregular astigmatism and myopia
and leading to mild to marked impairment in the quality of
vision.
The deﬁnitive cause underlying the development of kera-
toconus remains unclear. However, it appears to be a hetero-
geneous condition that may be produced by a variety of un-
related abnormalities of a metabolic and biochemical nature.
The most common presentation of keratoconus is as a spo-
radic disorder, in which only a signiﬁcant minority of pa-
tients exhibit a family history with autosomal dominant or
recessive transmission [2].
The morphological signs of keratoconus include forma-
tion of Fleischer’s ring—a pigmented ring that results from
the accumulation of ferritin particles in the cytoplasm of
epithelial cells and widened intercellular spaces—as shown
by electron microscopy [3], breaks in Bowman’s membrane,
ﬁlledwithcells,collagen,andPAS-positive material [4],stro-
mal thinning and abnormal keratocyte morphology [5], and
endothelial polymorphism [6]. In histopathological and bio-
chemical studies, keratoconic corneas are characterized by
increased levels of proteases and other catabolic enzymes,
decreased levels of tissue inhibitors of metalloproteinases
(TIMPs), increased collagenolytic activity, signiﬁcantly in-
creased expression of IL-4 receptors, apoptotic cell death of
keratocytes, and dramatic changes in collagen orientation
and distribution [7–11].
A number of medical and surgical approaches have been
usedinthetreatmentofkeratoconus.First-linetreatmentfor
patients with keratoconus is to ﬁt rigid gas-permeable (RGP)
contact lenses [12]. However, RGPs do not slow the rate of
progression of the cone but merely improve visual acuity.
The irregular shape of the cornea means that these lenses are
challenging to ﬁt, and the procedure requires a great deal of
time and patience, with RGP ﬁtting becoming more diﬃcult
and less successful as disease severity progresses. Moreover,
owing to the formation of raised subepithelial nodular scars
at or near the cone apex, contact lens intolerance can occur
due to erosion and discomfort [13].
Intrastromal corneal ring segment (Intacs) implantation
is a minimally invasive surgical procedure for keratoconic
corneasthatﬂattensthecentralcornealcurvaturewhenspec-
tacles or contact lenses are no longer eﬀective in improving2 Journal of Ophthalmology
visual acuity. The long-term tolerance of Intacs in kerato-
conic eyes without any signiﬁcant sight-threatening compli-
cations has been reported in several studies [14, 15]. How-
ever, like contact lenses, they do not aﬀect the corneal tissue
nor do they arrest or slow keratoconus progression; instead
they address the refractive consequences of the pathology
by changing the shape of the cornea. The mechanical tech-
nique of tunnel creation can cause epithelial defects at
the keratotomy site, anterior and posterior perforations,
shallow or uneven placement of the segments, introduction
ofepithelialcellsintothechannel,andstromalthinning[16].
The femtosecond laser has been reported to reduce these
complications due to more precise localization of the chan-
nel [17]. A rare but very important complication of Intacs
is postimplantation infection, which may occur even many
months after the initial procedure [18].
Keratoconus is one of the most common indications for
keratoplasty worldwide and is in fact the leading indication
in some countries [19]. Between 10% and 20% of kerato-
conuspatientsrequireakeratoplasty,andtheprocedureisin-
creasingly indicated in the more advanced stages. The in-
dications for keratoplasty in keratoconic patients are visual
acuity below 0.5 despite optimal correction, intolerance to
contact lenses, progressive corneal thinning, a decentered
cone, and the presence of opacities in the visual axis. Howe-
ver, keratoplasty is not exempted from complications and
limitations. Publications on most of the common type of
keratoplasty—penetrating keratoplasty (PK)—have shown
poor graft survival rates, due primarily to the continual loss
of donor endothelial cells [20]. Early suture removal, as well
as suture technique and graft size, has been suggested as
playing a crucial role in graft failure [21]. Graft neovascu-
larization may be a further factor associated with increased
risk of graft rejection [22].
A particular problem in PK is recurrence of keratoconus
caused by progressive thinning of the recipient peripheral
stroma [23]. PK for keratoconus is associated with a high
degree of graft astigmatism that may limit or delay visual
rehabilitation. In some patients, a stable visual outcome may
take several years to achieve. Another limitation of kerato-
plastyisthecuttingofcornealnerves,leadingtoreducedcor-
neal sensitivity [24].
As e c o n ds u r g i c a lo p t i o nf o rk e r a t o c o n u si sad e e pa n t e -
rior lamellar keratoplasty (DALK), involving exchange of
only the epithelium and stroma. This approach has the ad-
vantage of preserving the endothelium of the recipient cor-
nea, thus reducing risk of infection and rejection. The DALK
technique involves manual dissection, which often yields an
uneven bed and an irregular interface with suboptimal visual
outcome. Recent improvements in surgical technique and
advances in instrumentation have helped to improve the
match between patient and donor corneas, leading to visual
outcomes that are comparable with those after PK [25].
Inrecentyears,theabove-mentionedtreatmentstrategies
havebeensupplementedbycollagencross-linkingusingUVA
light and riboﬂavin (vitamin B2). This is a relatively new
approach,whichdirectlytargetsstromalinstability.Unlikeall
previous keratoconus management techniques, it is the only
approach designed to arrest the progression of the disease.
In conformity with the agreement reached at the Third
Corneal Cross-Linking Congress 2007 (Zurich, Switzerland),
we will use the term CXL throughout this paper to denote
the combined treatment using riboﬂavin and UVA light.
The idea of using CXL for corneal stiﬀening was con-
ceived in Germany in the 1990s [26]. The impressive clinical
results initially achieved in Germany have prompted world-
wide use of CXL. Currently, there are over 300 centers per-
forming CXL in Europe, and the technique has also been
used in Canada since 2008. The US Food and Drug Admin-
istration (FDA) recently approved the start of three clinical
trials in the United States.
2. Background to Collagen Cross-Linking
Collagen I is the major macromolecular constituent of the
cornealstroma,althoughcollagentypesIII,V,andVIarealso
represented. The corneal stroma possesses the mechanical
strength needed to form the anterior coat of the eye, whilst
maintaining the high degree of transparency required for
light transmission. Light transmission through the cornea
is a result of a particular, cornea-speciﬁc arrangement of
collagen ﬁbrils. Corneal collagen uniquely forms small
(32nm), uniformly spaced ﬁbrils that are organized into
larger bundles or ﬁbers (termed corneal lamellae) of varying
thickness (1-2μm) and width (5–100μm) that are arranged
in interweaving orthogonal layers throughout the stroma.
Theyare thinner and more interwoven in the anterior cornea
[27]. The characteristic collagen ﬁbril arrangement in the
cornea is believed to be maintained by the inﬂuence of dif-
ferent molecular subtypes within collagen ﬁbrils and by pro-
teoglycan macromolecules which associate in a speciﬁc man-
ner within the collagen.
Collagen is synthesized by keratocytes in the form of
its precursor molecule, called procollagen, which has two
additional peptides, one at each end. In the extracellular
space, specialized enzymes known as procollagen proteinases
remove the two extension peptides from the ends of the mol-
ecule. The processed molecule, now referred to as collagen,
undergoesposttranslationalmodiﬁcationandbeginstoform
ﬁbrils and then ﬁbers. This precisely controlled, enzyme-
regulated process involves the enzyme lysyl oxidase and
results in oxidation of the amino acids lysine and hydroxyly-
sine to their respective aldehydes, which condense with other
aldehydes to form intra- and intermolecular cross-links.
Another mechanism that changes the physical proper-
ties which inﬂuence the strength of the stromal tissue is
nonenzymatic glycation, a phenomenon that is related to the
reduced metabolic turnover of collagen and occurs through
the reaction of collagen with glucose and its oxidation pro-
ducts. The twin ﬁndings that keratoconus progression slows
with age and that keratoconus is uncommon in diabetic
patients are related to collagen cross-linking via nonenzy-
matic glycation [28, 29].
The induction of additional cross-links is a well-estab-
lished method for tissue stabilization in the polymer indus-
tries, in the preparation of prosthetic heart valves, for hard-
eningdentistryﬁllings,andfortissuehardeninginpathology
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various methods, for example, nonenzymatic glycation, irra-
diation using UV light with or without photosensitizer, and
aldehyde reactions.
The microscopic correlate of decreased corneal rigidity
in keratoconus has been attributed to reductions in collagen
cross-links and in molecular bonds between neighboring
stromal proteoglycans. In light of this knowledge, additional
cross-linkinduction in thecornealstromaby photopolymer-
ization was proposed as a means of stiﬀening the cornea and
hence of slowing disease progression.
3. Cross-Linkingto Stabilizethe Cornea
By actively increasing the degree of covalent bonding be-
tween and within the molecules of extracellular matrix, such
as collagen type I and proteoglycans, therapeutic cross-link-
ing was reasonably expected to enhance corneal rigidity and
to slow or even arrest the progression of keratoconus. To in-
vestigate the possibility of cross-link induction in corneal
stromal tissue, enucleated porcine eyes were divided into
eight test groups (10 eyes each) that were treated with UV-
light (254nm), 0.5% riboﬂavin, 0.5% riboﬂavin and UV-
light(365nm),5%riboﬂavinandbluelight(436nm),5%ri-
boﬂavin and sunlight, and the chemical agents glutaralde-
hyde (0.1% and 1%) and Karnovsky’s solution (0.1%) [31,
32].
Measurement of biomechanical properties revealed that
the greatest stiﬀening eﬀect occurred after treatment with
1% glutaraldehyde. Statistically signiﬁcant stiﬀening was
also achieved in all groups except for UV-light alone and
riboﬂavin alone.
Among all the protocols developed, the combination of
UVA-light with riboﬂavin was selected for future experi-
ments. The other cross-linking methods were recognized as
being impractical in a clinical setting because of cytotoxic-
ity and development of corneal haze and scarring (e.g., glu-
taraldehyde treatment) or application problems and pro-
longed treatment times (e.g., glyceraldehydes).
Riboﬂavin (vitamin B2) is the precursor of ﬂavin
mononucleotide (FMN) and ﬂavin adenine dinucleotide
(FAD), which are coenzymes that play a crucial role in the
metabolism of proteins, fats, and carbohydrates. Riboﬂavin
is an essential constituent of living cells and is noncytotoxic.
It acts as a photomediator, considerably increasing the
absorption of UVA light on exposure to corneal stoma. It has
been demonstrated that absorption of UVA light within the
lamellae of corneal stroma is approximately 30%, whereas
combinationwiththephotomediatorpropertiesofriboﬂavin
increases this absorption from 30% to 95% [31, 32]. Fol-
lowing exposure, riboﬂavin is excited into a triplet state
thereby generating reactive oxygen species: singlet oxygen
and superoxide anions then react with available groups near-
by. The precise mechanism of CXL at the molecular level
has not yet been elucidated; currently, all evidence for CXL
is indirect and chemical proof is awaited. One of the most
plausible mechanisms of collagen cross-linking in CXL is
thought to be the creation of additional chemical bonds be-
tweenhistidine,hydroxyproline,hydroxylysine,tyrosine,and
threonine amino-acid residues. Importantly, CXL can also
causecross-linkingofotherclassesofmacromoleculeswithin
the corneal stroma, such as proteoglycans, either to one ano-
ther or to collagen molecules [33].
4. ExperimentalStudies to Assess Corneal
Response to CXL andIts Effectiveness
Experimental studies in rabbits have demonstrated dose-
dependent keratocyte damage in a CXL procedure with
surface irradiance ranging from 0.75 to 4mW/cm2 [34]. At
a surface irradiance of 3mW/cm2 complete cell loss was ob-
served in rabbit corneas, as shown by histology and in vivo
CLSM [35, 36], whereas the same surface irradiance led
to cell loss only in the anterior 250–300μm of the corneal
stroma in humans [37].
Experimental studies have shown numerous Ki-67-posi-
tive ﬁbroblasts shortly after cross-linking [35, 36], whereas
only a few α-SMA-positive myoﬁbroblasts were detected in
the central cross-linked area [38]. Histopathological examin-
ation of human CXL-treated corneas has conﬁrmed these
ﬁndings by immunohistochemical analysis for Ki-67 and α-
SMA[39].Thisevidenceindicatesthattheactivationofkera-
tocytes after corneal cross-linking occurs mainly by means of
their transformation into ﬁbroblasts. This may explain why
no (or only mild) opacities have been observed after cross-
linking in the above-mentioned studies, bearing in mind
that the degree of opacity correlates directly with the num-
ber of activated keratocytes.
It is known that TGF-β triggers the diﬀerentiation of
myoﬁbroblasts from ﬁbroblasts [40]. TGF-β is released by
injured epithelial cells, and it can easily reach the adjacent
stroma by penetrating the basement membrane if the latter
is defective and irregular. In CXL, the epithelial sheet is re-
moved while basement membrane integrity is retained; this
feature may explain the almost complete absence of myo-
ﬁbroblasts and only mild (or even absent) opaciﬁcation in
the central treated area.
Endothelial cell density is regarded as a vitally important
criterion for CXL safety. The possible cytotoxic eﬀect of CXL
has been carefully investigated in vitro in porcine endo-
thelial cell cultures [41] and in experiments in rabbits [42],
where dose-dependent endothelial cell loss was found. The
latter study demonstrated necrotic and apoptotic cell death
accompanied by signiﬁcant edema at a standard surface UVA
dose of 3mW/cm2. It was shown later, however, that the
endothelial monolayer had already regained its integrity 1
week after CXL, a ﬁnding that can be attributed to the pro-
liferative capability of rabbit endothelial cells [35, 36].
It has been shown that Young’s modulus and corneal
rigidity are abnormally decreased in keratoconic eyes [43].
The biomechanical eﬀect of CXL on cornea has been stud-
ied in enucleated human and porcine eyes, and stress-
strain measurements were performed to evaluate changes
in corneal rigidity after CXL [44]. A signiﬁcant increase in
corneal rigidity was shown in treated corneas, as indicated
by a rise in stress. Increases in Young’s modulus were also
measured both in porcine and human corneas (by factors of
1.8 and 4.5, resp.). Further investigations of biomechanical
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eﬀect in anterior than in posterior stroma, both for enucle-
ated porcine and human corneas [45]. These ﬁndings cor-
relate positively with measurements of the thermomechani-
cal behavior of collagen-cross-linked porcine corneas which
showed a higher shrinkage temperature in the anterior stro-
ma compared to the posterior stroma due to the higher de-
gree of cross-linking of the anterior stroma [46].
Long-lasting improvements in the biomechanical prop-
erties of corneal tissue have been conﬁrmed in rabbit studies
f o ru pt o8m o n t h sa f t e rC X L[ 47]. Morphologically, the
eﬀect of CXL has been demonstrated by measuring collagen
ﬁbril diameter in rabbit corneas [48]; transmission electron
microscopy revealed a statistically signiﬁcant increase in
collagen ﬁber diameter in both anterior and posterior stro-
ma, although this eﬀect was more pronounced in the ante-
rior stroma. The morphological eﬀect of CXL has also been
investigated using immunoﬂuorescence. In one recent study,
corneas with Fuchs endothelial dystrophy and bullous kera-
topathy from patients who had undergone CXL 7 to 90
days prior to penetrating keratoplasty were investigated by
immunoﬂuorescence for collagen type I and compared with
control groups with same disorders [49]. Cross-linked cor-
neas showed a ﬂuorescent anterior lamellar zone with con-
densed and highly organized collagen ﬁbers, which was not
the case in the non-cross-linked group. The intensity of ﬂuo-
rescent staining was shown to decrease gradually in an ante-
rior-posteriordirection.Itshouldbealsonotedthatthesame
study demonstrated a diminution of the cross-linking eﬀect
over time.
CXL has been reported to have a certain impact on the
biochemical properties of corneal tissue by increasing the
resistance of corneal matrix against digestion by proteolytic
enzymes such as pepsin, trypsin, and collagenase [50]. The
authors attribute the stabilizing biochemical eﬀect of CXL to
alterations in the tertiary structure of collagen ﬁbrils, thus
denying the proteolytic enzymes access to their target sites.
It has been proposed that a positive correlation exists
between corneal stiﬀness and intraocular pressure (IOP)
[51]. On the basis of this correlation, an increase in IOP
can be expected following CXL as indirect conﬁrmation of
the eﬃcacy of cross-linking. In fact, IOP increases have been
recorded in patients after CXL, reﬂecting increased corneal
rigidity [52–54].
Two-photon microscopy has been used in rabbit corneas
to visualize cross-linking eﬀects on cells and collagen after
CXL by detecting second harmonic generation (SHG) and
autoﬂuorescence [55]. In this study, the grade of cross-
linking was quantiﬁed by autoﬂuorescence lifetime measure-
ments. CXL eﬀects were detected for up to 2 weeks in the
anterior stroma. Future experiments with longer follow-up
are required to determine the stability of these eﬀects.
5. Corneal Response to CXL In Vivo
Alongside histological studies in animals, in vivo confocal
laser-scanning microscopy (CLSM) now provides a nonin-
vasive modality for observing the corneal response to CXL.
In vivo CLSM oﬀers obvious advantages as a noninvasive
imaging technique that permits dynamic investigations to be
conducted over long observation periods [56]. Importantly,
in vivo CLSM not only provides an overview of the tissues
but also allows quantiﬁcation of acquired images, thus
yielding quantitative as well as qualitative data, and this is
a key aspect when evaluating the safety and duration of
the eﬀects achieved. The ﬁrst results obtained with in vivo
CLSM after CXL were published in 2006 [57]. This study
demonstrated epithelial regeneration and normal morphol-
ogy as early as day 5 after CXL. Subepithelial stromal nerve
ﬁbers were noted to have disappeared immediately after
CXL: initial signs of regeneration were observed 1 month
aftertheoperationandcontinuedthroughoutthepostopera-
tive period, with normal morphology and corneal sensitivity
being restored after 6 months. In the same patients, dis-
appearanceofkeratocytesintheanteriorstromaandrarefac-
tion in the posterior stroma were reported soon after treat-
ment [58]. In good agreement with previous experimental
studies, a repopulation process was demonstrated, reveal-
ing activated keratocytes in the anterior and intermediate
stroma. Normal endothelial morphology and density were
observed by in vivo CLSM during the entire follow-up
period. These ﬁndings were conﬁrmed in a larger patient
cohortthatwasfollowedusinginvivoCLSMforupto3years
[59]. Interestingly, this study with a longer follow-up showed
that, despite complete nerve ﬁber regeneration at 6 months
postoperatively, the plexus structure could not be deﬁned
until1yearafterCXL.AlaterinvivostudywithCLSM,again
with 3-year follow-up, conﬁrmed these ﬁndings [60]. In
this study, occasional inﬂammatory cells were present in the
diﬀerent epithelial layers 1 month after CXL. Importantly,
this had never been reported previously in patients, whereas
experimental animal studies had revealed inﬂammatory cell
activation in corneal stroma after CXL [35, 61]. Notably, the
authors also showed that the degree of stromal changes ob-
served after the ﬁrst week varied among patients and was
unrelatedtotheseverityofkeratoconus.UsinginvivoCLSM,
Kymionis et al. [62] have shown that tissue alterations after
CXL are quite similar in patients with keratoconus and post-
LASIK corneal ectasia.
In vivo CSLM has revealed early and late demarcation
lines between treated and untreated stroma. Demarcation
lines have also been detected by slit-lamp examination [63]
andanteriorsegmentopticalcoherencetomography[64].All
the aforementioned in vivo CLSM studies have yielded rela-
tively similar results regarding the cellular and extracellular
changes after CXL. Although in vivo CLSM is an indispens-
able tool for the dynamic sequential study of wound healing
after CXL, the technique is limited in that it depicts only
small areas (300μm) and image interpretation is based on
morphological features and reﬂectivity. It is still strongly rec-
ommended that every excised cornea should be investigated
by electron microscopy and immunohistochemistry.
6. ClinicalResults
Widely accepted parameters for evaluating the clinical out-
come of refractive corrections and CXL include uncorrected
visual acuity (UCVA), best corrected visual acuity (BCVA),Journal of Ophthalmology 5
uncorrected distance visual acuity (UDVA), corrected dis-
tancevisualacuity(CDVA),apexcurvature,andtopography-
derived outcomes of maximum and average keratometry
values.
A prospective, nonrandomized pilot study published in
2003 reported the earliest clinical experiences in a series of
23 eyes with moderate or advanced progressive keratoconus
[65]. During follow-up, which lasted for between 3 months
and 4 years, not only disease progression was at least halted,
but, in 70% cases, there was also a statistically signiﬁcant
improvement in BCVA, correlating with a reduction of the
maximal keratometry readings by 2 diopters and of the
refractive error by 1.14 diopters.
In an uncontrolled retrospective study, Raiskup-Wolf
et al. [66] showed that the ﬂattening process continues over
a period of years: they followed a large cohort of patients
(480 eyes of 272 patients) for up to 6 years and reported
arrested keratoconus progression and signiﬁcant improve-
ments in visual acuity. The long-term stabilization of kera-
toconic corneas without signiﬁcant side-eﬀects has also been
demonstrated in 44 eyes for up to 48 months after CXL [67],
also accompanied by a reduction in the mean K value by 2
diopters and gradually increasing improvements in UCVA
and BCVA during the observation period. The statistical
signiﬁcance of these values was maintained after 36 and 48
months of follow up.
Vinciguerra et al. [68] have described the outcome of
CXLin28eyeswithprogressivekeratoconus,usingthefellow
eye as control. This nonrandomized study revealed a statisti-
cally signiﬁcant improvement in UCVA and BCVA, with a
reduction in the steepest simulated keratometry meridian by
asmuchas6.16diopters.Keratoconusintheuntreatedfellow
eye showed progression over the same period.
In light of experimental studies reporting increased
corneal stiﬀness after CXL, eﬀorts have also been undertaken
to evaluate biomechanical parameters such as corneal hys-
teresis and corneal resistance factor after CXL [69, 70]. Using
the Ocular Response Analyzer, both studies revealed only
slight, statistically nonsigniﬁcant changes in biomechanical
parameters. This inconsistency has been attributed to the
diﬀerent methodologies used and to inherent diﬀerences
b e t w e e ni nv i t r oa n di nv i v om o d e l s .C o m p a r i s o n sb e t w e e n
treated and untreated eyes of the same patients, performed
over a 1-year period following CXL, showed signiﬁcant ﬂat-
tening and hence decreases in keratoconus indices in the
CXL-treated cornea; these ﬁndings were seen as indicating a
shift toward a more regular corneal shape, whereas the same
parameters in the control eyes indicated disease progression
[71]. All these studies have concluded that the improvement
in vision after CXL is produced by a decrease in astigmatism
and corneal curvature as well as by an increase in corneal
rigidity, leading to topographical homogenization.
Despite the positive outcomes reported from nonran-
domized clinical studies, these ﬁndings are still preliminary
and should be interpreted with caution. It is clear that
conclusive evidence regarding the eﬀects of CXL will emerge
onlyfrommultiplerandomizedcontrolledtrials(RCTs)with
a more robust design, and, to date, the literature on CXL
includes only a very small number of such RCTs. In the
Melbourne study, which was conducted in 49 patients, statis-
tically signiﬁcant diﬀerences were observed between control
and treatment groups in terms of BCVA and K values for up
to 12 months after CXL [72]. More recently, another group
has published an RCT reporting on one-year results after
CXL for the treatment of keratoconus and corneal ectasia
[73]. CXL was shown to be eﬀective in improving UDVA,
CDVA, the maximum K value, and the average K value. Ker-
atoconus patients displayed greater improvement in topo-
graphic measurements than patients with corneal ectasia.
Combination of CXL with other treatment modalities
also appears to be useful for enhancing clinical outcomes in
keratoconus management. The combination of topography-
guided PRK with CXL is reported to be an optimal method
for attaining greater eﬀects in progressive keratoconus [74,
75], as reﬂected in rapid and signiﬁcant improvements in
visualacuity(bothUCVAandBCVA)andmarkedcorrection
ofcornealirregularities,asshownbytopographicevaluation.
Comparison of sequential versus same-day simultaneous
CXL and topography-guided PRK demonstrated the greater
impact of the same-day procedure in reducing K values, im-
proving visual acuity, and lessening corneal haze [76]. Fur-
thermore, the addition of CXL to Intacs insertion has result-
ed in signiﬁcantly greater clinical improvements in kerato-
conus than Intacs insertion alone [77]. However, these data
are preliminary, and further conﬁrmation is required from
future studies.
7.AlternativeStrategies
Although CXL has proved itself in clinical practice, eﬀorts
are still being made to modify the standard protocol to
increase patient safety and comfort. Two factors in particular
are critical to ensure the success of CXL therapy: a certain
minimumcornealthicknesspriortoCXLandtheguaranteed
presence of a speciﬁc concentration of riboﬂavin. The stand-
ard protocol for CXL uses 0.1% riboﬂavin in 20% dextran.
Quite recently, a novel protocol using hypoosmolar
riboﬂavin solution has been developed for the management
of thin corneas [78]. The hypoosmolar solution achieved
preoperative swelling of thin corneas, thus enabling CXL to
be undertaken and keratoconus progression to be arrested
in all cases treated. It should be mentioned, however, that
all corneas included had a minimum stromal thickness of
323μm. Importantly, CXL failure has been reported in an
extremely thin cornea, suggesting that a minimum pre-
operative stromal thickness of 330μm is needed for success-
ful CXL [79].
The widely accepted standard protocol for CXL involves
corneal epithelial debridement to facilitate the penetration
of riboﬂavin into the stroma. However, deepithelialization
is accompanied by pain, foreign body sensation, and dis-
comfort in the form of burning and tearing for many days.
Moreover,epithelialdebridementreducestotalcornealthick-
ness, and this can have dramatic repercussions in extremely
thin corneas. Researchers and clinicians have therefore
been motivated to develop a variant of the standard CXL
technique without deepithelialization, thus oﬀering patients6 Journal of Ophthalmology
safer and faster CXL while retaining the eﬃcacy of the stand-
ard approach.
An immunoﬂuorescence confocal imaging study on enu-
cleated porcine eyes has shown that, without previous deep-
ithelialization, CXL had no eﬀe c to nc o l l a g e nt y p eIo r g a n i -
zation, conﬁrming the belief that the intact epithelium acts
as barrier to riboﬂavin absorption [80]. The necessity for
deepithelialization as an initial step in CXL has also been
demonstrated in vitro on porcine eyes by other investigators
[81, 82]. Analysis of corneal light transmission spectra in
these studies clearly revealed that riboﬂavin was able to
penetrate into the stroma only in completely abraded cor-
neas.
In one clinical study, deepithelialization was customized
on the basis of pachymetric measurements so that the cor-
nea was left intact in regions thinner than 400μma n dr e -
moved in regions with adequate thickness [83]. This study
demonstrated an increase in the safety of CXL, as well as
satisfactory results in stabilizing keratoconus, but without
detailing special eﬀects and alterations in speciﬁc areas. To
evaluate intrastromal concentrations of riboﬂavin in CXL
with and without epithelial debridement, half of the corneas
(from keratoconus patients enrolled for keratoplasty) under-
went CXL with abrasion and half without [84]. Quantitative
HPLC analysis demonstrated that a theoretically safe and
eﬀective concentration of riboﬂavin was obtained only after
epithelial debridement, conﬁrming previous results. In a
similar comparative study, customized deepithelialization
wasperformedintwokeratoconuspatients,andanteriorseg-
ment OCT and in vivo CLSM were used to compare CXL
eﬀects in epithelium-on and epithelium-oﬀ regions of the
same cornea [85]. Both techniques detected strong CXL
eﬀects (e.g., the demarcation line and keratocyte disappear-
ancefollowedbyhaze)inthedeepithelializedregions,where-
as the corneal stroma under the intact epithelium seemed to
be spared.
Another morphological modiﬁcation of the CXL proto-
col without deepithelialization proposes the use of benzalko-
niumchloride(BAC)[86],givenitsabilitytoincreaseepithe-
lial permeability by loosening tight junctions [87]. In an
experimental comparative study, CXL incorporating appli-
cation of 0.005% BAC was performed on rabbit corneas with
intact epithelium [88]. The biomechanical stiﬀening eﬀect
was reduced by about one-ﬁfth compared with standard
CXL. Increasing the BAC concentration further to 0.02%
clearly aﬀected epithelial permeability to riboﬂavin, thus
increasing the absorption coeﬃcient and achieving great-
er stiﬀening eﬀects, as reﬂected in a signiﬁcant increase in
Young’s modulus and stress-strain values [89]. Moreover,
study of resistance to enzymatic digestion revealed that
corneas with intact epithelium treated with CXL without
BAC dissolved in collagenase solution after 6 days, whereas
corneas with intact epithelium undergoing CXL with BAC
behaved like controls (standard CXL protocol) and did not
dissolve even after 14 days.
In a prospective, consecutive clinical study in patients
with progressive keratoconus, CXL with intact epithelium
and pretreatment with BAC, and other substances enhancing
epithelial permeability revealed less pronounced eﬀects than
standard CXL [90]. Despite a positive eﬀect on CDVA, cor-
neal curvature was maintained and did not improve.
The long-term eﬃcacy and possible side eﬀects of CXL
without deepithelialization require further assessment in
randomized,controlledstudieswithlongerobservationperi-
ods.
8. Other Applicationsof CXL
As the technique has grown in popularity in recent years,
other potential applications for CXL in ophthalmology have
been proposed.
8.1. Ectasia. Ectasia following corneal excimer laser refrac-
tive surgery is a postoperative thinning of the cornea, en-
countered mainly after LASIK. In the most advanced cases,
penetrating keratoplasty may even be required. Thanks to
its ability to stabilize the biomechanics of the cornea, CXL
has been proposed as a therapeutic method of arresting kera-
tectasia progression. The ﬁrst study to investigate the advan-
tages of CXL in post-LASIK ectasia showed an increase in
biomechanical stability suﬃcient to prevent the progression
of keratectasia [91]. A reduction in maximum keratometric
readings and an increase in biomechanical stability were also
conﬁrmedinalargergroup(10patients)forupto12months
[92]. CXL has been reported to improve BSCVA in eyes with
post-LASIK ectasia without any signiﬁcant side eﬀects [93].
In vivo CLSM disclosed relatively similar corneal alterations
after CXL both in keratoconic and in post-LASIK corneal
ectasia eyes [62]. The positive impact of CXL in conjunction
with PRK has been shown in a case of post-LASIK ectasia
[94]. As a qualifying remark, it should be pointed out that
thelongestfollow-upinthesestudieshasbeen1year.Despite
these promising early results, studies with longer follow-
up and larger patient numbers are needed to evaluate the
eﬀectiveness and safety of CXL in the management of post-
LASIK keratectasia.
Another form of corneal ectasia is pellucid marginal
degeneration (PMD)—a noninﬂammatory disorder charac-
terized by a peripheral band of thinning of the corneal seg-
ment between the 4 o’clock and 8 o’clock positions. One case
report describes a patient with bilateral PMD who under-
went CXL unilaterally, on the side with more profound ecta-
sia [95]. The treated eye was examined during the ﬁrst year
after treatment. Reduced corneal astigmatism and improved
visual acuity were detected at 3 months and remained stable
through the 12-month interval. The endothelial cell count
and corneal thickness remained unchanged from the pre-
operative assessment to 12 months, conﬁrming the safety of
CXL. A signiﬁcant positive clinical outcome has also been
obtained in PMD patients by combining CXL with photo-
refractive keratectomy [96] or with topography-guided tran-
sepithelial surface ablation [97].
8.2. Keratitis. Keratitis is a corneal disease that may result
from infection (with bacteria, fungi, yeasts, viruses, and
amoebae) or from immunological disorders (sterile kerati-
tis). Attempts have been made in recent years to assess the
eﬀects of CXL in infectious keratitis, with a possible viewJournal of Ophthalmology 7
to making it a treatment option. The antibacterial eﬀect-
iveness of CXL has been demonstrated in vitro against some
common pathogens, selected from a panel of clinical ocular
isolates obtained from patients with severe bacterial keratitis
[98]. CXL has also exhibited antimicrobial eﬀects in vitro
againstfungalpathogens,suchasCandidaalbicans,Fusarium
sp., and Aspergillus fumigatus [99]. The ability of CXL to
inhibitpathogengrowthhasthepotentialtomakeitaneﬀec-
tive tool in the management of infectious keratitis. In a small
case series with bacterial and fungal keratitis, Iseli et al. [100]
demonstrated immediate regression of the corneal melting
process and a decrease in inﬁltrate size after CXL in most
patients. A later study has conﬁrmed this observation and
demonstrated symptomatic relief and arrest of melting pro-
gression in corneas with bacterial keratitis [101].
CXL has also been beneﬁcial in treating a patient with
Escherichia coli keratitis [102], leading to complete healing of
corneal ulceration, regression of edema, and disappearance
of painful symptoms.
TheantimicrobialeﬀectsofCXLhavetwopossiblemech-
anisms, and, in all probabilities, these operate in synergy.
Firstly, the pathogens implicated in corneal melting are
known to act by enzymatic digestion. Since CXL has been re-
ported to increase tissue resistance to enzymatic digestion
[50], the improvement in symptoms can be attributed to
the greater resistance of corneal tissue to enzyme activity.
Secondly, the phenomenon of cell apoptosis after CXL may
include not only keratocytes but also pathogens, thus arrest-
ing the infectious process.
Despite these promising results, both studies referred to
above were limited in terms of case numbers, and further
extensive investigations are needed before CXL can be incor-
porated into routine clinical practice for the treatment of
keratitis.
8.3. Corneal Edema. Endothelial dysfunction results in cor-
neal swelling (edema) and visual impairment. The most
common conditions associated with edema are bullous kera-
topathy and Fuchs dystrophy. In an experimental study,
Wollensak et al. [103] demonstrated in enucleated porcine
eyes that the CXL procedure altered the swelling pattern of
the cornea, minimizing hydration. It is hypothesized that
CXL strengthens the interﬁber attachments, thereby reduc-
ing the space for ﬂuid accumulation and so increasing the
opticalclarityofthecornea.TheantiedematouseﬀectofCXL
potentially makes it a useful tool in the clinic for treating
corneal edema. Reduced corneal edema, increased corneal
clarity, and improved visual acuity were demonstrated dur-
ing the 2-month follow-up period after CXL in two cases
of bullous keratopathy associated with corneal ulcer or
infectious keratitis [104]. CXL performed in eyes with endo-
thelial decompensation and nonhealing ulcers led to signif-
icant beneﬁt in only half of nonhealing ulcer cases, whereas
a signiﬁcant decrease in corneal thickness and improvement
in symptoms was noted in 10 of 11 corneas with endo-
thelial decompensation for up to 3 months after treatment
[105]. However, in another clinical study where CXL was
performed in patients with bullous keratopathy and Fuchs
dystrophy, measurements of central corneal thickness for up
to 6 months indicated that CXL reduced edema only tem-
porarily [106] .M o r e o v e r ,i na d v a n c e dc a s e so fc o r n e a l
edema, CXL had only little eﬀect, suggesting that the great-
er stromal impairment in these patients interfered with ribo-
ﬂavin penetration, thus resulting in less beneﬁt. On the
other hand, stable reductions in corneal thickness have been
demonstrated in bullous keratopathy and Fuchs dystrophy
for up to 8 months after CXL [107]. This inconsistency can
be explained by the fact that Wollensak et al. [107] used
pretreatment with 40% glucose for 1 day prior to CXL,
allowing dehydration of the cornea and more precise esti-
mation of corneal thickness. The importance of dehydrating
the swollen cornea prior to CXL has also been demonstrat-
ed by another group in Fuchs dystrophy patients with
various degrees of edema [108]. Although the results re-
ported by Wollensak et al. [107] appear to be more reliable,
their study included only a very limited number of patients.
Future studies with longer follow-up and larger patient
numbers are necessary to assess the eﬃcacy and limitations
of CXL in the treatment of corneal edema. At present, as a
minimally invasive and safe procedure, CXL can be recom-
mended at least for those patients awaiting keratoplasty.
9. Complications after CXL
Although CXL is one of the most promising developments
in the management of keratoconus, the potential for adverse
outcomes should not be underestimated.
9.1. Stromal Haze. Corneal scarring (diﬀuse subepithelial
opaciﬁcation) that was slow to resolve has been reported in a
41-year-old man after CXL; this complication responded to
topical application of steroids, eventually resolving gradually
afterseveralmonths[109].Subclinicalstromalhazethatdoes
not impair patients’ vision has also been detected by other
groups using confocal microscopy [59, 110]. Raiskup et al.
[111] demonstrated CXL-induced permanent corneal haze
inapproximately8.6%ofalltreatedeyes.Thehazeofvarying
degreesafterCXLtookupto12monthstoresolvecompletely
[66].
Interestingly, haze formation correlates positively in all
studies with the stage of keratoconus; all patients who
developed haze had advanced keratoconus, thinner corneas,
Vogt’s striae, and higher keratometry values. Consequently,
the development of haze may be attributed not to CXL itself
but to the stage of keratoconus. Objective quantiﬁcation of
the time course of CXL-induced haze suggests that it peaks at
1 month, plateaus at 3 months, and then gradually decreases
thereafter [112].
More recently, corneal haze formation has been reported
in the posterior stroma in 2 patients (7% of all treated cases)
after CXL [113]. Notably, both patients had mild rather than
advanced keratoconus. Even though haze developed near the
apexofthecone,awayfromthecentralvisualaxis,thesecases
indicate that not only keratoconus stage but other factors too
may have contributed to this phenomenon. Further research
is needed to investigate this aspect carefully with regard to
the safety of CXL.8 Journal of Ophthalmology
A far higher incidence of haze has been observed in
46.42% of keratoconic eyes treated with simultaneous cus-
tomized PRK and CXL [114]. Posterior linear stromal haze
was visualized clinically by slit-lamp biomicroscopy, and, in
the same corneas, in vivo CLSM revealed highly reﬂective,
spindle-shaped keratocytes, which are associated with stro-
mal repopulation and increased collagen deposition. Photo-
ablation is highly likely to have been the factor that co-
ntributed to the more common occurrence of haze with this
combined approach.
9.2. Keratitis. There is no direct evidence yet of any lowering
of the corneal immune mechanisms following CXL. Never-
theless, there is a major risk of infection after standard CXL
because the procedure involves deepithelialization followed
by the application of a soft contact lens. There has been one
case report of polymicrobial keratitis caused by Streptococcus
salivarius, Streptococcus oralis,a n dStaphylococcus sp. 3 days
afterCXL[115].Thepatientadmittedthathehadcleanedhis
bandage contact lens in his mouth, an action that was most
probably the cause of keratitis. Escherichia coli infection
occurred in a case 3 days after CXL, with multiple stromal
inﬁltrations and moderate anterior chamber inﬂammation
[116]. The bacterial keratitis was successfully treated with
fortiﬁed tobramycin and cephazolin eye drops for several
weeks. Furthermore, fungal keratitis has been reported as a
complication 22 days after CXL despite complete epithelial
recovery at day 5 [117]. Koppen et al. [118] have also pub-
lished a case report series concerning 4 patients who devel-
oped severe keratitis, resulting in corneal scarring within the
ﬁrst few days after CXL.
Acanthamoeba keratitis with corneal melting has been
reported in a 32-year-old woman 5 days following CXL
[119].Thepatientwasunawareofwearingabandagecontact
lens and repeatedly rinsed his face and eyelids with tap water.
Because of corneal perforation, a large therapeutic kera-
toplasty ` a chaud was performed.
A case report has shown that CXL can induce herpetic
keratitis with iritis even in patients with no history of
herpeticdisease[120].Followingsteroidsandacyclovirtreat-
ment,asigniﬁcantimprovementwasobserved,andtherewas
no evidence of herpetic disease recurrence 2 months postop-
eratively. The same group reported on the diﬀuse lamellar
keratitis during the ﬁrst posttreatment days [121], which
resolvedafterintensivetreatmentwithtopicalcorticosteroids
during the following 2 weeks.
More recently, 2 cases of keratopathy have been reported
after uneventful CXL for grade 3 keratoconus [122]. The
pathogenesis in these cases remained unidentiﬁed. Corneal
inﬁltrates slowly resolved after combined topical antibiotic/
antifungal/steroids treatment.
Although the incidence of keratitis is low in these studies,
it remains a very serious side eﬀect of CXL.
10. Concluding Remarks
CXL, a procedure that uses UVA light in conjunction
with riboﬂavin as a photomediator, creates new covalent
cross-links between collagen ﬁbrils, thus strengthening and
stabilizing the cornea. CXL is a topic that has been attracting
growing interest over the past decade. It has been shown
not only to arrest progression of keratectasia in progressive
keratoconusandpost-LASIKcorneasbutalsotoexertamod-
erately positive eﬀect on visual status. Corneal edema and
infectious keratitis have also been reported to beneﬁt from
CXL. Because most of the published clinical ﬁndings have
come from nonrandomized studies, further corroboration is
required from more robustly designed RCTs.
Attempts have been made to optimize CXL to minimize
the potential for risk in very thin corneas or to reduce patient
discomfort. The major safety concerns associated with CXL
are ocular surface damage and endothelial cell damage. Al-
though the safety of CXL has been demonstrated in numer-
ous experimental animal studies, outcomes in patients are
more complex than in animal models. Postoperative events
vary markedly, depending on the stage of keratoconus in pa-
tients treated. Edema, stromal haze, and infectious keratitis
have been reported as complications in the clinical setting-
albeit very rarely. Further studies are therefore needed to ex-
tensively investigate the safety of the CXL procedure.
Because collagen turnover in the stroma is known to
take several years, it remains unclear whether the changes
in corneal stability reported after CXL will be permanent or
whether its eﬀects are time limited. The long-term eﬀects of
standardandmodiﬁedprotocolsforCXLshouldbereviewed
thoroughly in studies with longer follow-up.
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